Immunoprecise antibodies receives nasdaq notification regarding minimum bid requirements

Victoria, british columbia--(business wire)---- $ipa #ai--immunoprecise antibodies ltd. (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutics company, announced today that the company received written notification (the "notification letter") from the nasdaq global market llc ("nasdaq") on august 19, 2024, indicating that the company is not in compliance with the minimum bid price requirement set forth in the nasdaq rule 5450(a)(1) based on the closing bid price of the company's common shares.
NDAQ Ratings Summary
NDAQ Quant Ranking